These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 1412144

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H, Fager G.
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [Abstract] [Full Text] [Related]

  • 3. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS, Bacon SP, Illingworth DR.
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [Abstract] [Full Text] [Related]

  • 4. [Effects and side effects of a 1-year treatment of primary hypercholesterolemia with simvastatin].
    Brocard JJ, Keller U, Oberhänsli A, Riesen WF.
    Schweiz Med Wochenschr; 1991 Jun 29; 121(26):977-83. PubMed ID: 1862314
    [Abstract] [Full Text] [Related]

  • 5. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM, Thompson GR.
    Q J Med; 1990 Feb 29; 74(274):165-75. PubMed ID: 2111917
    [Abstract] [Full Text] [Related]

  • 6. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
    Riesen WF, Keller U, Del Bufalo A, Reutter FW, Baur HR, Golay A, Bertel O, Kummer H, Kistler H, Ammann F.
    Schweiz Med Wochenschr; 1989 Dec 02; 119(48):1719-23. PubMed ID: 2694363
    [Abstract] [Full Text] [Related]

  • 7. [Hypercholesterolemia: therapeutic approach].
    Alessandri C, Peverini F.
    Clin Ter; 1991 Jun 30; 137(6):373-97. PubMed ID: 1832610
    [Abstract] [Full Text] [Related]

  • 8. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
    Slater EE, MacDonald JS.
    Drugs; 1988 Jun 30; 36 Suppl 3():72-82. PubMed ID: 3076125
    [Abstract] [Full Text] [Related]

  • 9. [HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
    Geisel J, Oette K, Burrichter H.
    Fortschr Med; 1990 Feb 10; 108(4):71-2, 75-6. PubMed ID: 2312032
    [Abstract] [Full Text] [Related]

  • 10. A review of clinical trials comparing HMG-CoA reductase inhibitors.
    Illingworth DR, Tobert JA.
    Clin Ther; 1994 Feb 10; 16(3):366-85; discussion 365. PubMed ID: 7923304
    [Abstract] [Full Text] [Related]

  • 11. [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
    Darioli R, Bovet P, Brunner HR, Bercher L.
    Schweiz Med Wochenschr; 1990 Jan 27; 120(4):85-91. PubMed ID: 2305221
    [Abstract] [Full Text] [Related]

  • 12. [Effectiveness and tolerability of simvastatin in patients with moderate-to-severe hypercholesterolemia. Results of a 12-month study].
    Ghizzoni G, Rusconi C, Faggiano P, Sabatini T, Oneglia C, Gardini A.
    Minerva Cardioangiol; 1993 Mar 27; 41(3):105-9. PubMed ID: 8510811
    [Abstract] [Full Text] [Related]

  • 13. [Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up].
    Wenke K, Thiery J, Meiser B, Arndtz N, Seidel D, Reichart B.
    Z Kardiol; 1995 Feb 27; 84(2):130-6. PubMed ID: 7717016
    [Abstract] [Full Text] [Related]

  • 14. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
    Saxenhofer H, Weidmann P.
    Ther Umsch; 1990 Jun 27; 47(6):509-13. PubMed ID: 2375007
    [Abstract] [Full Text] [Related]

  • 15. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
    Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE.
    Drug Metab Dispos; 1990 Jun 27; 18(2):138-45. PubMed ID: 1971563
    [Abstract] [Full Text] [Related]

  • 16. [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
    Berioli S, Bentivoglio M, Conti R, Osanna RA, Savino K, Zollino L, Corea L.
    Cardiologia; 1990 Apr 27; 35(4):335-40. PubMed ID: 2245435
    [Abstract] [Full Text] [Related]

  • 17. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
    Morris MJ, Gilbert JD, Hsieh JY, Matuszewski BK, Ramjit HG, Bayne WF.
    Biol Mass Spectrom; 1993 Jan 27; 22(1):1-8. PubMed ID: 8431499
    [Abstract] [Full Text] [Related]

  • 18. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I, Spinler SA, Johnson NE.
    Ann Pharmacother; 1995 Jan 27; 29(7-8):743-59. PubMed ID: 8520093
    [Abstract] [Full Text] [Related]

  • 19. [Effects of simvastatin on atherogenic blood lipid pattern].
    Alessandri C, Peverini F, Basili S, Barsi R, Paradiso M, Marotta P, Censi C, Cordova C, Balsano F.
    Recenti Prog Med; 1991 Apr 27; 82(4):225-9. PubMed ID: 1857842
    [Abstract] [Full Text] [Related]

  • 20. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
    Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM, Mantell G.
    Clin Ther; 1992 Apr 27; 14(5):708-17. PubMed ID: 1468089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.